A clinical trial is a term we have all heard and it encompasses many different types of approaches, some observational while others are interventional. There is much exciting research going on globally but that research cannot be translated into treatments that will benefit patients unless clinical trials are filled and we work together to promote and support the science.

Cure Parkinson’s International Linked Clinical Trials (iLCT) programme is a drug repurposing and repositioning initiative, that seeks to significantly reduce the time taken to bring much needed, and potentially curative treatments into the clinic for the Parkinson’s community. There are iLCT trials that are actively recruiting participants now.

Find out more about
Drug trials – The phases explained Blog: Unshakeable M.D. Physician, Patient, Advocate The International Linked Clinical Trials programme (iLCT)
iLCT studies recruiting now

We fund and support clinical trials which seek to slow, stop or reverse Parkinson’s. We have clinical trials within the International Linked Clinical Trials programme that are actively seeking people to take part now.

Read more here
Find other studies recruiting

New treatments for Parkinson’s will only become available after they have been tested in those volunteers affected by the disease.

Find out more
The Clinical Trials Charter

The Clinical Trials Charter has been developed by people with Parkinson’s and clinicians.

Find out more

Why take part in clinical research? 

Participation in clinical trials requires a certain amount of selfless commitment but it can also be a rewarding experience allowing those who dedicate their time and energy to be a part of something much larger; something that has the potential to make a life-changing difference in the lives of many.

For some, it is the possibility that if a study is investigating a drug, participants might benefit from the treatment before it is available to many.  Others sign up out of altruism, wanting to make a difference to future generations; and some join for curiosity to learn more about their Parkinson’s – essential if we are to develop personalised medicine solutions in the future.  Another key factor is that clinical trial participants will see the research study team frequently (whether online or in person) in addition to their usual Parkinson’s appointments. This means that any changes in a participant’s Parkinson’s can be discussed, and if possible, addressed.

There is emerging evidence that the research-active have better overall health outcomes, for example, a 2020 publication, by researchers at Cumbria Partnership NHS Foundation Trust, found that patients admitted to more research-active hospitals have more confidence in staff and are better informed about their condition and medication.

Read more of this study here

With special thanks to Soania Mathur, whose blog was used in some of the content of this page.

Related content

MAMS